134 related articles for article (PubMed ID: 34244783)
1. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
Neroutsos E; Athanasiadou I; Paisiou A; Zisaki K; Goussetis E; Archontaki H; Tsirigotis P; Kitra M; Grafakos S; Spyridonidis A; Dokoumetzidis A; Valsami G
J Pharm Pharmacol; 2021 Sep; 73(10):1340-1350. PubMed ID: 34244783
[TBL] [Abstract][Full Text] [Related]
2. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WP; Garbriel D; Serody J; Kirby S; Wiley J
Anticancer Drugs; 2004 Jun; 15(5):453-9. PubMed ID: 15166618
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.
Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
Int J Clin Pharm; 2020 Apr; 42(2):703-712. PubMed ID: 32140913
[TBL] [Abstract][Full Text] [Related]
4. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
[TBL] [Abstract][Full Text] [Related]
5. Limited Sampling Strategies Supporting Individualized Dose Adjustment of Intravenous Busulfan in Children and Young Adults.
Teitelbaum Z; Nassar L; Scherb I; Fink D; Ring G; Lurie Y; Krivoy N; Bentur Y; Efrati E; Kurnik D
Ther Drug Monit; 2020 Jun; 42(3):427-434. PubMed ID: 31479045
[TBL] [Abstract][Full Text] [Related]
6. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.
McCune JS; Baker KS; Blough DK; Gamis A; Bemer MJ; Kelton-Rehkopf MC; Winter L; Barrett JS
J Clin Pharmacol; 2013 Mar; 53(3):264-75. PubMed ID: 23444282
[TBL] [Abstract][Full Text] [Related]
7. Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved?
Buffery PJ; Allen KM; Chin PK; Moore GA; Barclay ML; Begg EJ
Ther Drug Monit; 2014 Feb; 36(1):86-92. PubMed ID: 24299921
[TBL] [Abstract][Full Text] [Related]
8. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.
Tesfaye H; Branova R; Klapkova E; Prusa R; Janeckova D; Riha P; Sedlacek P; Keslova P; Malis J
Ann Transplant; 2014 May; 19():214-24. PubMed ID: 24811685
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
Malär R; Sjöö F; Rentsch K; Hassan M; Güngör T
Pediatr Transplant; 2011 Sep; 15(6):580-8. PubMed ID: 21736681
[TBL] [Abstract][Full Text] [Related]
11. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
[TBL] [Abstract][Full Text] [Related]
12. A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation.
Hoffer E; Akria L; Tabak A; Scherb I; Rowe JM; Krivoy N
Ther Drug Monit; 2004 Jun; 26(3):331-5. PubMed ID: 15167637
[TBL] [Abstract][Full Text] [Related]
13. A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.
Philippe M; Neely M; Bertrand Y; Bleyzac N; Goutelle S
Clin Pharmacokinet; 2017 Apr; 56(4):435-447. PubMed ID: 27585476
[TBL] [Abstract][Full Text] [Related]
14. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
[TBL] [Abstract][Full Text] [Related]
15. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
Gaziev J; Nguyen L; Puozzo C; Mozzi AF; Casella M; Perrone Donnorso M; Gravina P; Sodani P; Marziali M; Isgrò A; Simone MD; Andreani M; Formosa A; Testi M; Federici G; Bernardini S; Lucarelli G
Blood; 2010 Jun; 115(22):4597-604. PubMed ID: 20237319
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
[TBL] [Abstract][Full Text] [Related]
17. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
[TBL] [Abstract][Full Text] [Related]
18. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
[TBL] [Abstract][Full Text] [Related]
19. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study.
Jansing T; Sanpakit K; Tharnpanich T; Jiranantakan T; Niphandwongkorn V; Chindavijak B; Suansanae T
Pediatr Hematol Oncol; 2021 May; 38(4):346-357. PubMed ID: 33656974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]